News Daily News Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI Yael L. Maxwell December 29, 2025
News Daily News Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC Michael O'Riordan June 25, 2025
News Daily News Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION Michael O'Riordan June 04, 2025
News Daily News ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients Michael O'Riordan March 26, 2025
News Daily News New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise Yael L. Maxwell May 08, 2024
News Daily News Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift Yael L. Maxwell May 03, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024
News Daily News Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest Michael O'Riordan January 30, 2024
News Daily News DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants Shelley Wood January 17, 2024
News Daily News No Safety Concerns Seen With Inclisiran in Large ORION Analysis Michael O'Riordan December 06, 2023
News Daily News For TAVI Patients With CAD, Lifetime Management Is Key: EAPCI Michael O'Riordan February 23, 2023
News Daily News UK’s NICE Recommends Lower-Risk Thresholds for Statin Therapy Michael O'Riordan January 20, 2023
News Daily News Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees Michael O'Riordan January 05, 2023
News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Daily News Less Occlusion, Hematomas With Distal Radial Access: Meta-analysis Michael O'Riordan November 22, 2022
News Daily News More Endpoints, More Problems: FDA Offers Advice for Multi-endpoint Trials Michael O'Riordan October 28, 2022
News Daily News SPRINT Turns Sluggish: Mortality Benefits Vanish Once Normal BP Care Resumes Michael O'Riordan October 18, 2022